INS and type 2 diabetes mellitus: Mesenchymal stem cell (MSC) therapy for type-2 diabetes has been shown to stimulate β-cell replication, differentiate into insulin producing cells as well as play a protective role within the endocrine pancreas [84], and studies in rodents have shown the ability to improve symptoms in streptozotocin-induced diabetic rats [85].